Wilhelm Krek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wilhelm Krek has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Christiane Wirbelauer
Friedrich Miescher Institut, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
2 shared publicationsAlain Martia
Friedrich Miescher Institut, Maulbeerstrasse 66, CH-4058, Basel, Switzerland
1 shared publicationCharles Catzavelos
Friedrich Miescher Institut, Maulbeerstrasse 66, CH-4058 Basel, Switzerland; ‡Department of Oral Pathology, University of California, San Francisco, CA 941430; §Department of Pathology and Laboratory of Medicine, and ‖Divisions of Cancer Research and Medical Oncology, Toronto Sunnybrook Regional Cancer Centre, and Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada; and ¶Novartis Pharma AG, Oncology, CH-4021 Basel, Switzerland
1 shared publicationFrancoise Reymond
Friedrich Miescher Institut, Maulbeerstrasse 66, CH‐4058, Basel, Switzerland
1 shared publicationFrançoise Reymond
Friedrich Miescher Institut , Maulbeerstrasse 66, CH-4058 Basel, Switzerland
1 shared publicationHedwig Sutterlüty
Friedrich Miescher Institut, Maulbeerstrasse 66, CH‐4058, Basel, Switzerland
1 shared publication
Latest Publications
- 17 April 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (9) , 5043-5048
Skp2 is oncogenic and overexpressed in human cancers
Skp2 is a member of the F-box family of substrate-recognition subunits of SCF ubiquitin–protein ligase complexes that has been implicated in the ubiquitin-mediated degradation of several key regulators of mammalian G 1 progression, including the cyclin-dependent kinase inhibitor p27, a dosage-dependent tumor suppressor protein. In this study, we examined Skp2 and p27 protein expression by immunohistochemistry in normal oral epithelium and in different stages of malignant oral cancer progression, including dysplasia and oral squamous cell carcinoma. We found that increased levels of Skp2 protein are associated with reduced p27 in a subset of oral epithelial dysplasias and carcinomas compared with normal epithelial controls. Tumors with high Skp2 (>20% positive cells) expression invariably showed reduced or absent p27 and tumors with high p27 (>20% positive cells) expression rarely showed Skp2 positivity. Increased Skp2 protein levels were not always correlated with increased cell proliferation (assayed by Ki-67 staining), suggesting that alterations of Skp2 may contribute to the malignant phenotype without affecting proliferation. Skp2 protein overexpression may lead to accelerated p27 proteolysis and contribute to malignant progression from dysplasia to oral epithelial carcinoma. Moreover, we also demonstrate that Skp2 has oncogenic potential by showing that Skp2 cooperates with H-Ras G12V to malignantly transform primary rodent fibroblasts as scored by colony formation in soft agar and tumor formation in nude mice. The observations that Skp2 can mediate transformation and is up-regulated during oral epithelial carcinogenesis support a role for Skp2 as a protooncogene in human tumors.
- 17 April 2001
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (9) , 5043-5048
Skp2 is oncogenic and overexpressed in human cancers
Skp2 is a member of the F-box family of substrate-recognition subunits of SCF ubiquitin–protein ligase complexes that has been implicated in the ubiquitin-mediated degradation of several key regulators of mammalian G 1 progression, including the cyclin-dependent kinase inhibitor p27, a dosage-dependent tumor suppressor protein. In this study, we examined Skp2 and p27 protein expression by immunohistochemistry in normal oral epithelium and in different stages of malignant oral cancer progression, including dysplasia and oral squamous cell carcinoma. We found that increased levels of Skp2 protein are associated with reduced p27 in a subset of oral epithelial dysplasias and carcinomas compared with normal epithelial controls. Tumors with high Skp2 (>20% positive cells) expression invariably showed reduced or absent p27 and tumors with high p27 (>20% positive cells) expression rarely showed Skp2 positivity. Increased Skp2 protein levels were not always correlated with increased cell proliferation (assayed by Ki-67 staining), suggesting that alterations of Skp2 may contribute to the malignant phenotype without affecting proliferation. Skp2 protein overexpression may lead to accelerated p27 proteolysis and contribute to malignant progression from dysplasia to oral epithelial carcinoma. Moreover, we also demonstrate that Skp2 has oncogenic potential by showing that Skp2 cooperates with H-Ras G12V to malignantly transform primary rodent fibroblasts as scored by colony formation in soft agar and tumor formation in nude mice. The observations that Skp2 can mediate transformation and is up-regulated during oral epithelial carcinogenesis support a role for Skp2 as a protooncogene in human tumors.
- Open Access
- 16 October 2000
- Published by Springer Nature in The EMBO Journal
- Vol. 19 (20) , 5362-5375
The F‐box protein Skp2 is a ubiquitylation target of a Cul1‐based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts
The ubiquitin protein ligase SCFSkp2 is composed of Skp1, Cul1, Roc1/Rbx1 and the F‐box protein Skp2, the substrate‐recognition subunit. Levels of Skp2 decrease as cells exit the cell cycle and increase as cells re‐enter the cycle. Ectopic expression of Skp2 in quiescent fibroblasts causes mitogen‐independent S‐phase entry. Hence, mechanisms must exist for limiting Skp2 protein expression during the G/G1 phases. Here we show that Skp2 is degraded by the proteasome in G/G1 and is stabilized when cells re‐enter the cell cycle. Rapid degradation of Skp2 in quiescent cells depends on Skp2 sequences that contribute to Cul1 binding and interference with endogenous Cul1 function in serum‐deprived cells induces Skp2 expression. Furthermore, recombinant Cul1–Roc1/Rbx1–Skp1 complexes can catalyse Skp2 ubiquitylation in vitro . These results suggest that degradation of Skp2 in G/G1 is mediated, at least in part, by an autocatalytic mechanism involving a Skp2‐bound Cul1‐based core ubiquitin ligase and imply a role for this mechanism in the suppression of SCFSkp2 ubiquitin protein ligase function during the G/G1 phases of the cell cycle.
- 16 October 2000
- Published by Springer Nature in The EMBO Journal
- Vol. 19 (20) , 5362-5375
Open AccessThe F‐box protein Skp2 is a ubiquitylation target of a Cul1‐based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts
The ubiquitin protein ligase SCFSkp2 is composed of Skp1, Cul1, Roc1/Rbx1 and the F‐box protein Skp2, the substrate‐recognition subunit. Levels of Skp2 decrease as cells exit the cell cycle and increase as cells re‐enter the cycle. Ectopic expression of Skp2 in quiescent fibroblasts causes mitogen‐independent S‐phase entry. Hence, mechanisms must exist for limiting Skp2 protein expression during the G/G1 phases. Here we show that Skp2 is degraded by the proteasome in G/G1 and is stabilized when cells re‐enter the cell cycle. Rapid degradation of Skp2 in quiescent cells depends on Skp2 sequences that contribute to Cul1 binding and interference with endogenous Cul1 function in serum‐deprived cells induces Skp2 expression. Furthermore, recombinant Cul1–Roc1/Rbx1–Skp1 complexes can catalyse Skp2 ubiquitylation in vitro . These results suggest that degradation of Skp2 in G/G1 is mediated, at least in part, by an autocatalytic mechanism involving a Skp2‐bound Cul1‐based core ubiquitin ligase and imply a role for this mechanism in the suppression of SCFSkp2 ubiquitin protein ligase function during the G/G1 phases of the cell cycle.
- Open Access
- 15 May 2000
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 113 (10) , 1687-1694
Association of human ubiquitin-conjugating enzyme CDC34 with the mitotic spindle in anaphase
Present in organisms ranging from yeast to man, homologues of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme CDC34 have been shown to play important roles in the regulation of cell cycle progression and checkpoint function. Here we analyze the expression and intracellular localization of endogenous CDC34 during mammalian cell cycle progression. We find that CDC34 protein is constitutively expressed during all stages of the cell cycle. Immunofluorescence experiments reveal that during interphase, endogenous CDC34 is localized to distinct speckles in both the nucleus and the cytoplasm. The presence of CDC34 in these compartments has also been established by biochemical fractionation experiments. Interestingly, nuclear localization depends on the presence of specific carboxy-terminal CDC34 sequences that have previously been shown to be required for CDC34's cell cycle function in Saccharomyces cerevisiae. Finally, we find that in anaphase and not during early stages of mitosis, CDC34 colocalizes with (beta)-tubulin at the mitotic spindle, implying that it may contribute to spindle function at later stages of mitosis. Taken together, these results support a model in which CDC34 ubiquitin-conjugating enzyme functions in the regulation of nuclear and cytoplasmic activities as well as in the process of chromosome segregation at the onset of anaphase in mammalian cells.
- 15 May 2000
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 113 (10) , 1687-1694
Open AccessAssociation of human ubiquitin-conjugating enzyme CDC34 with the mitotic spindle in anaphase
Present in organisms ranging from yeast to man, homologues of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme CDC34 have been shown to play important roles in the regulation of cell cycle progression and checkpoint function. Here we analyze the expression and intracellular localization of endogenous CDC34 during mammalian cell cycle progression. We find that CDC34 protein is constitutively expressed during all stages of the cell cycle. Immunofluorescence experiments reveal that during interphase, endogenous CDC34 is localized to distinct speckles in both the nucleus and the cytoplasm. The presence of CDC34 in these compartments has also been established by biochemical fractionation experiments. Interestingly, nuclear localization depends on the presence of specific carboxy-terminal CDC34 sequences that have previously been shown to be required for CDC34's cell cycle function in Saccharomyces cerevisiae. Finally, we find that in anaphase and not during early stages of mitosis, CDC34 colocalizes with (beta)-tubulin at the mitotic spindle, implying that it may contribute to spindle function at later stages of mitosis. Taken together, these results support a model in which CDC34 ubiquitin-conjugating enzyme functions in the regulation of nuclear and cytoplasmic activities as well as in the process of chromosome segregation at the onset of anaphase in mammalian cells.
- 27 March 2000
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1470 (2) , R29-R34
ISREC Conference ‘Cancer and the Cell Cycle’: 26–30 January 1999, Lausanne, Switzerland
- 27 March 2000
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1470 (2) , R29-R34
ISREC Conference ‘Cancer and the Cell Cycle’: 26–30 January 1999, Lausanne, Switzerland
- 1 March 1999
- Published by Elsevier in Experimental Cell Research
- Vol. 247 (2) , 554-562
Association of Human SCFSKP2Subunit p19SKP1with Interphase Centrosomes and Mitotic Spindle Poles
- 1 March 1999
- Published by Elsevier in Experimental Cell Research
- Vol. 247 (2) , 554-562
Association of Human SCFSKP2Subunit p19SKP1with Interphase Centrosomes and Mitotic Spindle Poles
- 1 February 1998
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 8 (1) , 36-42
Proteolysis and the G1-S transition: the SCF connection
- 1 February 1998
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 8 (1) , 36-42
Proteolysis and the G1-S transition: the SCF connection